Stockscreener 앱 받기
44.41
1.58%
0.69
시간 외 거래:
44.42
0.01
+0.02%
Sanofi Adr 주식(SNY)의 최신 뉴스
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - tradingview.com
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews - GlobeNewswire Inc.
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi SA (HAM:SNW2) Stock Price, Trades & News - GuruFocus
NOK Stock Slides As ADR Weakness Puts Pressure On Bulls - StocksToTrade
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
NOK Stock Slips Again As ADR Weakness Worries Traders - StocksToTrade
Sanofi stock slides as price lingers below the long-term average - Traders Union
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sahm
9 New 5-Star Stocks This Week - Morningstar
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
662283 Forecast — Price Target — Prediction for 2027 - TradingView
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims - Sahm
Sanofi faces EU probe, shares steady after Friday’s Reuters report - ad-hoc-news.de
Sanofi SA Sponsored ADR Actuals & Estimates (NASDAQ:SNY) - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY) - Seeking Alpha
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - AD HOC NEWS
MacroGenics stock rises on $24.5M Sanofi milestone payment By Investing.com - Investing.com Nigeria
Muted Sanofi hits fresh 52-week low, shares trade well below analyst targets - AD HOC NEWS
Form 6K Sanofi ADR For: 22 June By Investing.com - Investing.com Australia
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals - ChartMill
Sanofi S.A. Stock (FR0000127771): Deutsche Bank trims target but sticks with Buy - Ad-hoc-news.de
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sahm
Sanofi S.A. Stock (FR0000120578): FDA accelerated approval for Tzield puts diabetes franchise in foc - AD HOC NEWS
0.30%
2.20%
자본화:
|
볼륨(24시간):